Project Grant R01CA292654
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$554K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
This federal Project Grant award for $680,453, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to investigate the use of cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer (mCRPC). The 5-year study will pursue three specific aims: 1) determine if baseline cell-free tumor DNA (ctDNA) fragmentomics scores are prognostic...
The National Cancer Institute (NCI) awarded a $433,157 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Endeavor Health Clinical Operations, a division of Northshore University HealthSystem Research Institute, for a study titled "Lipid-Rich Macrophages at the Tumor-Adipose Interface: A New Target for Locally-Invasive Prostate Cancer Therapy." The 2-year project, beginning on July 18, 2024, will investigate the role of lipid-rich adipose tissue macrophages in prostate cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Albert Einstein College of Medicine provides $535,334 in funding over a 5-year period from January 1, 2025 to December 31, 2029. The research aims to investigate the non-autonomous role of androgen signaling in prostate tumorigenesis, specifically focusing on the tumor niche function of stromal androgen receptor (AR) signaling in GLI1-expressing cells. The study proposes a series of experiments...
The National Cancer Institute (NCI) awarded a $393,401 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Washington State University (WSU) to develop a PSMA-targeted small-molecule dual drug conjugate (SMDDC) for treating metastatic castration-resistant prostate cancer (mCRPC) and other PSMA-positive malignancies. The project aims to assess the spatio-temporal cargo release of a PSMA-targeted SMDPC and determine the potency enhancement of a SMDDC bearing dual chemotherapeutic payloads...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $624,001.00 to New York University School of Medicine to develop a novel class of drug candidates called multivalent peptoid conjugates (MPCs) that can effectively antagonize the androgen receptor (AR) in prostate cancer. The goal is to create MPC-based therapeutics that can stop the growth of prostate cancer cells, including those resistant to standard anti-androgen agents like...
This Project Grant award of $564,543.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Weill Medical College of Cornell University supports research to understand how the androgen receptor (AR) is reprogrammed from its normal growth-suppressive role to an oncogenic factor in prostate cancer. The research aims to reactivate the AR growth-suppressive program in advanced prostate cancer, and identify key cofactors and modifiers that mediate the switch...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $606,869 to Case Western Reserve University to conduct research on mechanisms of androgen receptor (AR) inverse agonists in advanced prostate cancer. The 5-year project, which began on July 5, 2024, aims to map the epigenetic mechanisms driving AR-mediated gene expression programs in metastatic castration-resistant prostate cancer (mCRPC) using sophisticated molecular and...
The federal Project Grant award R01CA287075, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop an innovative, minimally invasive liquid biopsy assay to identify molecular subtypes of lethal prostate cancer. The $649,486 award to Cedars-Sinai Medical Center will leverage an expansive cohort of clinically annotated prostate cancer specimens to: 1) perform analytical validation of large oncosome isolation technologies for clinical...
The National Cancer Institute (NCI) awarded a $205,700 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer. The research aims to explore a novel combination approach of DNA repair inhibition and targeted therapy to prevent the emergence of resistance. Through analysis of clinical samples, cell lines, and...
The National Cancer Institute (NCI) awarded a $762,258 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Cedars-Sinai Medical Center. The project aims to develop and test a natural language processing (NLP) and artificial intelligence (AI) system that provides real-time feedback to patients and physicians on key risks and rewards discussed during prostate cancer treatment consultations. The goal is to improve patient decision-making and physician risk...